aVIDEX announces agreement with Active Biotech AB
Active's Anyara cancer immunotherapeutic is a fusion protein of an antibody directed against 5T4 (an antigen found on solid tumours) and a molecule derived from a bacterial superantigen that stimulates T cells to kill the tumour cell. The optimised, second generation Anyara product is in Phase I clinical trials in non-small cell lung cancer patients in the US and Norway. A similar first generation candidate immunotherapeutic has already successfully concluded Phase II trials in renal and pancreatic cancer.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.